Quantitative analysis of vitreous and plasma concentrations of brilliant blue g after use as a surgical adjuvant in chromovitrectomy

Hiroshi Enaida, Yuji Kumano, Akifumi Ueno, Shigeo Yoshida, shintaro nakao, Shinichiro Numa, Takaaki Matsui, Tatsuro Ishibashi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

PURPOSE: To measure the concentration of brilliant blue G (BBG) in vitreous and plasma after use as a surgical adjuvant for staining and peeling of the internal limiting membrane to determine potential systemic adverse effects. METHODS: This study was designed as a prospective, interventional, clinical, case series. Five eyes from five patients with macular hole or epiretinal membrane underwent BBG-assisted internal limiting membrane and epiretinal membrane removal. The vitreous samples were obtained and stored at the end of surgery in all five cases. The plasma specimens were extracted and stored at the end of the operation, after 4 hours, and after 7 days post operation. For BBG analysis of plasma and vitreous, high-performance liquid chromatography coupled with tandem mass spectrometric detection was used. RESULTS: Brilliant blue G was not detected in plasma from all five cases at the three points of measurement. The mean vitreous BBG concentration was 34.5 ± 23.7 ng/mL (range, 11.3-70.9 ng/mL). Postoperative progress was good, and adverse effects were not observed in any of the five cases. CONCLUSION: Brilliant blue G, which remained at low levels in the vitreous cavity, was not found in the systemic blood flow after the operation. Thus, any adverse effects of systemic BBG would be avoided.

Original languageEnglish
Pages (from-to)2170-2174
Number of pages5
JournalRetina
Volume33
Issue number10
DOIs
Publication statusPublished - Nov 1 2013

Fingerprint

Epiretinal Membrane
Retinal Perforations
Membranes
coomassie Brilliant Blue
brilliant blue
High Pressure Liquid Chromatography
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Quantitative analysis of vitreous and plasma concentrations of brilliant blue g after use as a surgical adjuvant in chromovitrectomy. / Enaida, Hiroshi; Kumano, Yuji; Ueno, Akifumi; Yoshida, Shigeo; nakao, shintaro; Numa, Shinichiro; Matsui, Takaaki; Ishibashi, Tatsuro.

In: Retina, Vol. 33, No. 10, 01.11.2013, p. 2170-2174.

Research output: Contribution to journalArticle

Enaida, Hiroshi ; Kumano, Yuji ; Ueno, Akifumi ; Yoshida, Shigeo ; nakao, shintaro ; Numa, Shinichiro ; Matsui, Takaaki ; Ishibashi, Tatsuro. / Quantitative analysis of vitreous and plasma concentrations of brilliant blue g after use as a surgical adjuvant in chromovitrectomy. In: Retina. 2013 ; Vol. 33, No. 10. pp. 2170-2174.
@article{c460cd306eba4926830d87a6c3b10d3c,
title = "Quantitative analysis of vitreous and plasma concentrations of brilliant blue g after use as a surgical adjuvant in chromovitrectomy",
abstract = "PURPOSE: To measure the concentration of brilliant blue G (BBG) in vitreous and plasma after use as a surgical adjuvant for staining and peeling of the internal limiting membrane to determine potential systemic adverse effects. METHODS: This study was designed as a prospective, interventional, clinical, case series. Five eyes from five patients with macular hole or epiretinal membrane underwent BBG-assisted internal limiting membrane and epiretinal membrane removal. The vitreous samples were obtained and stored at the end of surgery in all five cases. The plasma specimens were extracted and stored at the end of the operation, after 4 hours, and after 7 days post operation. For BBG analysis of plasma and vitreous, high-performance liquid chromatography coupled with tandem mass spectrometric detection was used. RESULTS: Brilliant blue G was not detected in plasma from all five cases at the three points of measurement. The mean vitreous BBG concentration was 34.5 ± 23.7 ng/mL (range, 11.3-70.9 ng/mL). Postoperative progress was good, and adverse effects were not observed in any of the five cases. CONCLUSION: Brilliant blue G, which remained at low levels in the vitreous cavity, was not found in the systemic blood flow after the operation. Thus, any adverse effects of systemic BBG would be avoided.",
author = "Hiroshi Enaida and Yuji Kumano and Akifumi Ueno and Shigeo Yoshida and shintaro nakao and Shinichiro Numa and Takaaki Matsui and Tatsuro Ishibashi",
year = "2013",
month = "11",
day = "1",
doi = "10.1097/IAE.0b013e31828e69d6",
language = "English",
volume = "33",
pages = "2170--2174",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Quantitative analysis of vitreous and plasma concentrations of brilliant blue g after use as a surgical adjuvant in chromovitrectomy

AU - Enaida, Hiroshi

AU - Kumano, Yuji

AU - Ueno, Akifumi

AU - Yoshida, Shigeo

AU - nakao, shintaro

AU - Numa, Shinichiro

AU - Matsui, Takaaki

AU - Ishibashi, Tatsuro

PY - 2013/11/1

Y1 - 2013/11/1

N2 - PURPOSE: To measure the concentration of brilliant blue G (BBG) in vitreous and plasma after use as a surgical adjuvant for staining and peeling of the internal limiting membrane to determine potential systemic adverse effects. METHODS: This study was designed as a prospective, interventional, clinical, case series. Five eyes from five patients with macular hole or epiretinal membrane underwent BBG-assisted internal limiting membrane and epiretinal membrane removal. The vitreous samples were obtained and stored at the end of surgery in all five cases. The plasma specimens were extracted and stored at the end of the operation, after 4 hours, and after 7 days post operation. For BBG analysis of plasma and vitreous, high-performance liquid chromatography coupled with tandem mass spectrometric detection was used. RESULTS: Brilliant blue G was not detected in plasma from all five cases at the three points of measurement. The mean vitreous BBG concentration was 34.5 ± 23.7 ng/mL (range, 11.3-70.9 ng/mL). Postoperative progress was good, and adverse effects were not observed in any of the five cases. CONCLUSION: Brilliant blue G, which remained at low levels in the vitreous cavity, was not found in the systemic blood flow after the operation. Thus, any adverse effects of systemic BBG would be avoided.

AB - PURPOSE: To measure the concentration of brilliant blue G (BBG) in vitreous and plasma after use as a surgical adjuvant for staining and peeling of the internal limiting membrane to determine potential systemic adverse effects. METHODS: This study was designed as a prospective, interventional, clinical, case series. Five eyes from five patients with macular hole or epiretinal membrane underwent BBG-assisted internal limiting membrane and epiretinal membrane removal. The vitreous samples were obtained and stored at the end of surgery in all five cases. The plasma specimens were extracted and stored at the end of the operation, after 4 hours, and after 7 days post operation. For BBG analysis of plasma and vitreous, high-performance liquid chromatography coupled with tandem mass spectrometric detection was used. RESULTS: Brilliant blue G was not detected in plasma from all five cases at the three points of measurement. The mean vitreous BBG concentration was 34.5 ± 23.7 ng/mL (range, 11.3-70.9 ng/mL). Postoperative progress was good, and adverse effects were not observed in any of the five cases. CONCLUSION: Brilliant blue G, which remained at low levels in the vitreous cavity, was not found in the systemic blood flow after the operation. Thus, any adverse effects of systemic BBG would be avoided.

UR - http://www.scopus.com/inward/record.url?scp=84887109961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887109961&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e31828e69d6

DO - 10.1097/IAE.0b013e31828e69d6

M3 - Article

VL - 33

SP - 2170

EP - 2174

JO - Retina

JF - Retina

SN - 0275-004X

IS - 10

ER -